A5045284474- Systemic Lupus Erythematosus Research
- Renal Diseases and Glomerulopathies
- Vasculitis and related conditions
- Liver Diseases and Immunity
- Pregnancy and Medication Impact
- Monoclonal and Polyclonal Antibodies Research
- Pregnancy and preeclampsia studies
- Renal Transplantation Outcomes and Treatments
- Systemic Sclerosis and Related Diseases
- Atherosclerosis and Cardiovascular Diseases
- IgG4-Related and Inflammatory Diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Reproductive System and Pregnancy
- T-cell and B-cell Immunology
- Cell Adhesion Molecules Research
- Urticaria and Related Conditions
- Chronic Kidney Disease and Diabetes
- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- Renal and Vascular Pathologies
- Eosinophilic Disorders and Syndromes
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Complement system in diseases
- Otitis Media and Relapsing Polychondritis
- Autoimmune Bullous Skin Diseases
Istituti di Ricovero e Cura a Carattere Scientifico
2005-2025
IRCCS Humanitas Research Hospital
2021-2025
Humanitas University
2021-2025
University of Milan
1999-2023
RELX Group (United States)
2020-2023
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2012-2021
University of Milano-Bicocca
2021
Ospedale Maggiore
2010-2020
International Society of Nephrology
2020
Pediatric Nephrology of Alabama
2018-2020
Our objective was to update the EULAR recommendations for management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007-12/2017), followed by modified Delphi method, form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity prevention flares. Hydroxychloroquine is recommended all patients with lupus, dose not exceeding 5 mg/kg real body weight. During chronic...
Objective To update the 2012 EULAR/ERA–EDTA recommendations for management of lupus nephritis (LN). Methods Following EULAR standardised operating procedures, a systematic literature review was performed. Members multidisciplinary Task Force voted independently on their level agreeement with formed statements. Results The changes include treatment targets, use glucocorticoids and calcineurin inhibitors (CNIs) end-stage kidney disease (ESKD). target therapy is complete response (proteinuria...
Objectives To update the EULAR recommendations for management of systemic lupus erythematosus (SLE) based on emerging new evidence. Methods An international Task Force formed questions systematic literature reviews (January 2018–December 2022), followed by formulation and finalisation statements after a series meetings. A predefined voting process was applied to each overarching principle recommendation. Levels evidence strengths recommendation were assigned, participants finally provided...
Only few data are available on pregnancy in patients with lupus nephritis (LN) diagnosed before conception. The aim of this study was to identify the risk factors for complicated women pre-existing LN.In a multicentre study, we collected 113 pregnancies occurring 81 biopsy-proven LN. Primary outcomes were fetal loss including perinatal death and renal flares during 12 months after pregnancy. Univariate logistic regression analyses used predictors outcomes.Renal biopsy performed 7.2 +/- 4.9...
<h3>Abstract</h3> Cost reduction of high-throughput technologies has enabled the monitoring same biological sample across multiple omics studies and timepoints. The goal is to combine longitudinal multi-omics data detect temporal relationships between molecules interactions layers. This can finally lead uncover new regulation mechanisms that could be responsible for causing complex phenotype or disease. However integration diverse still challenging due heterogeneous designs. Moreover,...
Objectives: To evaluate the role of immunological tests for monitoring lupus nephritis (LN) activity. Methods: C3, C4, anti-dsDNA and anti-C1q antibodies were prospectively performed over 6 years in 228 patients with LN. Results: In membranous LN only differentiated proteinuric flares from quiescent disease (p = 0.02). However, this group 46% occurred a normal value versus 20% proliferative antiphospholipid (APL), 33% levels 14.5% that APL-negative LN, showed slightly better sensitivity...
Background. Few data are available about the very long-term outcome of patients with proliferative lupus nephritis.
Objectives To evaluate changes in demographic, clinical and histological presentation, prognosis of lupus nephritis (LN) over time. Patients methods We studied a multicentre cohort 499 patients diagnosed with LN from 1970 to 2016. The 46-year follow-up was subdivided into three periods (P): P1 1970–1985, P2 1986–2001 P3 2002–2016, accordingly grouped based on the year diagnosis. Predictors patient renal survival were investigated by univariate multivariate proportional hazards Cox regression...
Summary Background and objectives The discovery of different podocyte autoantibodies in membranous nephropathy (MN) raises questions about their pathogenetic clinical meaning. This study sought to define antibody isotypes correlations; compare levels MN, other glomerulonephritides, controls; determine association with outcomes. Design, setting, participants, & measurements Serum IgG 1 , 3 4 against aldose reductase (AR), SOD2, α-enolase (αENO) were measured at diagnosis 186 consecutive...
BackgroundFew data are available on allograft survival at 15 years, the impact and predictors of recurrence original disease in renal transplanted patients with IgA nephropathy (IgAN).
Neutrophil extracellular traps (NET) expose modified antigens for autoantibodies in vasculitis. Little is known about levels and removal pathways of NET systemic lupus erythematosus (SLE), especially nephritis (LN). We determined circulating defined large subsets patients with incident SLE (iSLE), some whom had new-onset nephritis.Serum (ELISA), DNase1/DNase1L3 DNase activity (functional assay) were 216 iSLE [103 LN (iLN)], 50 other primary glomerulonephritis, healthy controls. Ex vivo...
Renal targets of autoimmunity in human lupus nephritis (LN) are unknown. We sought to identify autoantibodies and glomerular target antigens renal biopsy samples from patients with LN determine whether the same can be detected circulation. Glomeruli were microdissected 20 characterized by proteomic techniques. Serum large cohorts systemic erythematosus (SLE) without other glomerulonephritides tested. Glomerular IgGs recognized 11 podocyte antigens, reactivity varying pathology. Notably, IgG2...
Short-term predictive endpoints of chronic kidney disease (CKD) are needed in lupus nephritis (LN). We tested response to therapy at 1 year.We considered patients with LN who underwent renal biopsy followed by induction between January 1970 and December 2016. was assessed using the International Society Nephrology/Renal Pathology (2003) criteria National Institute Health (NIH) activity chronicity index. The outcome CKD. Response defined according EULAR/European League Against...